Unveiling the therapeutic potential of gut microbiota metabolites for the treatment of renal fibrosis based on network pharmacology study
Weiguo Yao, Jinlin Huo, Kun Liu, Pengyu Tao · 2026
Read Unveiling the therapeutic potential of gut microbiota metabolites for the treatment of renal fibrosis based on network pharmacology study by Weiguo Yao, Jinlin Huo, Kun Liu, Pengyu Tao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13283118.txt.
Description
Compounds made by gut microbes might slow kidney scarring, the hypothesis behind Weiguo Yao's 2026 network analysis. Kidney scarring worsens kidney function over time and lacks strong treatments. Products made by gut microbes affect body health, but their role here was unclear.
Databases of microbe products and disease genes were merged for the analysis. The overlap gave 47 shared targets tied to both sets. Core targets included JUN, IL6, IL1B, and AKT1 in the network results. Three products stood out as safe lead options: propionate, butyrate, and one indole acid. Docking tests showed stable binding to core targets. Lab proof is still needed before clinical use.
Catalog record
| CREATOR | Weiguo Yao, Jinlin Huo, Kun Liu, Pengyu Tao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36913 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |